The Egyptian Drug Authority has expressed concerns over the spread of misinformation about pharmaceuticals, warning that incorrect information can lead to harmful treatment decisions and even fatalities. According to Dr. Yas Ragab, assistant head of the authority, the increasing reach and influence of non-specialists or a limited number of specialists have compromised some standards of medical and scientific integrity in conveying drug information.
Dr. Ragab emphasized that the authority is taking steps to ensure that promotional content is accurate and reliable, as it directly affects public health. He noted that some products are registered and approved for circulation, while others are not, and that advertising claims can be misleading even for approved products. The authority is working to establish clear guidelines for advertising and promotional content.
The authority has identified that some advertisements and promotional materials for pharmaceuticals are not in line with regulatory requirements. Dr. Ragab stressed that only non-prescription drugs can be advertised, and that such advertisements must obtain approval from the authority. He also warned that making unsubstantiated claims about a product's efficacy or benefits can have serious consequences.
The authority is particularly concerned about products that are not registered, as their safety and efficacy cannot be verified. In such cases, the risks associated with their use can be significant, and the consequences can be fatal. Dr. Ragab assured that the authority is taking a firm stance on such products and enforcing penalties on companies that violate regulations.
According to Dr. Ragab, the authority's actions are aimed at protecting public health and ensuring that promotional content is accurate and reliable. He emphasized that the authority is committed to working with stakeholders to establish clear guidelines and regulations for advertising and promotional content. The authority's efforts are focused on preventing harm to the public.
The authority's enforcement actions can include warning letters, fines, and other regulatory measures. In cases where companies have registered products, the authority may take action against the company, including stopping dealings with them and shutting down their platforms. The authority is taking a proactive approach to monitoring and enforcing compliance.
The Egyptian Drug Authority's efforts to regulate promotional content and advertising are ongoing, with a focus on ensuring that the public has access to accurate and reliable information about pharmaceuticals. The authority's actions aim to promote public health and prevent harm from misinformation and unsubstantiated claims.
Key points
- The Egyptian Drug Authority is taking steps to regulate promotional content and advertising for pharmaceuticals to protect public health.
